Researchers conducted a systematic review and meta-analysis to determine the global prevalence of difficult-to-treat rheumatoid arthritis using the 2021 EULAR definition.
Nationally representative survey data revealed that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) use for obesity treatment more than tripled among US adults without diabetes between 2018 and ...
The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i. Real-world data show that treatment with glucagon-like peptide-1 receptor ...
Hispanic, Black non-Hispanic, White non-Hispanic adults more likely to use GLP-1 RA injectables than Asian non-Hispanics. (HealthDay News) — In 2024, 26.5 percent of adults with diagnosed diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback